From: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma
Characteristics/Data items | Number | Percent |
---|---|---|
Total patients | 29 | 100 |
Sex | ||
- Male | 17 | 58.6 |
- Female | 12 | 41.4 |
Mean age (years; range) | 62.4 (42 to 84) | |
ECOG performance score | ||
- 0 or 1 | 26 | 89.7 |
- 2 or 3 | 3 | 10.3 |
Karnofsky Index | ||
- 100% | 2 | 6.9 |
- 90% | 15 | 51.7 |
- 80% | 9 | 31.0 |
- 70% | 2 | 6.9 |
- 60% | 1 | 3.4 |
Mesothelioma cell type | ||
- epithelioid | 29 | 100 |
Clinical type | ||
- “dry” type | 8 | 27.6 |
- “wet” type | 12 | 41.4 |
- “mixed” type | 9 | 31.0 |
Alcohol consumption | ||
- no or minimal | 22 | 75.9 |
- daily alcohol intake | 7 | 24.1 |
Smoking habits | ||
- no | 18 | 62.0 |
- yes | 11 | 38.0 |
Primary tumor site at initial diagnosis | ||
- abdominal | 24 | 82.8 |
- thoracal | 5 | 17.2 |
Prior extended resection surgery | ||
- cytoreduction & HIPEC (CC-0 & CC-1) | 7 | 24.1 |
- abdominal debulking | 8 | 27.6 |
- pleuropneumonectomy | 2 | 6.9 |
- thoracotomy/decortication | 3 | 10.3 |
Prior surgical score (PSS) | ||
- PSS 0 | 11 | 27.5 |
- PSS 1 | 8 | 29 |
- PSS 2 | 6 | 15 |
- PSS 3 | 15 | 37.5 |
Extra-abdominal metastatic spread before PIPAC/PITAC | 13 | 44.8 |
- thoracal | 8 | 27.6 |
- mediastinal | 3 | 10.3 |
- abdominal wall | 2 | 6.9 |
No previous systemic chemotherapy | 8 | 27.6 |
- refused any systemic chemotherapy | 3 | 10.3 |
- stop due to severe side effects | 3 | 10.3 |
- new diagnosis of disease | 2 | 6.9 |
First line chemotherapy | 21 | 72.4 |
- Cisplatin & Pemetrexed | 17 | 58.6 |
- Pemetrexed mono | 3 | 10.3 |
- Carboplatin & Pemetrexed | 1 | 3.4 |
Second line chemotherapy | 8 | 27.6 |
- Cisplatin & Pemetrexed | 5 | 17.2 |
- Pemetrexed mono | 3 | 10.3 |
Third line chemotherapy | 2 | 6.9 |
- Pemetrexed mono | 2 | 6.9 |
Systemic chemotherapy & scheduled for PIPAC | 7 | 24.1 |
- Cisplatin & Pemetrexed | 4 | 13.8 |
- Pemetrexed mono | 3 | 10.3 |
Scheduled for PIPAC without systemic chemotherapy | 22 | 75.9 |